Genentech wins FDA approval for unique refillable treatment targeting blinding eye disease

//Genentech wins FDA approval for unique refillable treatment targeting blinding eye disease

Genentech wins FDA approval for unique refillable treatment targeting blinding eye disease

The FDA approval comes as Genentech and parent Roche face generic competition for Lucentis and other companies pursue longer-acting drugs for wet AMD patients.

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2021-10-22T21:51:23+00:00 October 22nd, 2021|Healthcare|

About the Author: